Replies to post #345882 on NorthWest Biotherapeutics Inc (NWBO)

[lindaliau]

https://www.sciencedirect.com/science/article/pii/S2329050120300085

This articles has a section reviewing Microden which is the device you are referring to. I think you just say things without doing the research on the things you say.

[biosectinvestor]

Here also is another article suggesting otherwise https://www.genengnews.com/sponsored/automated-reproducible-dendritic-cell-production/


“ Automated Reproducible Dendritic Cell Production
August 1, 2019

...

“ The current gold-standard method for generating DCs from monocytes has 11 laborious manual steps involving 15 hours of technician time. Steps include static culture and stimulation with cytokines contained in culture media using multiple T-flasks or well plates.

To address this manufacturing dilemma, market-leading Corning entered into an agreement with Flaskworks to commercialize MicroDEN, an automated fluidic system that allows for differentiation of monocytes into DCs utilizing continuous perfusion of differentiation media.

“Using an automated, perfusion-based process such as MicroDEN for dendritic cell production eliminates six manual steps, reduces the risk of contamination, and efficiently produces repeatable results in less time,” said Elizabeth Misleh, senior product line manager, bioprocess, at Corning Life Sciences. “It also eliminates the variability that can result from different levels of technician proficiency.”

The closed system provides consistent yields and requires only three hours of technician time during the week-long process (see figure). MicroDEN leverages the benefits of a polystyrene culture surface, similar to the manual method, to provide for removal of non-adherent cells. Up to 25 million DCs can be reproducibly generated per unit, an equivalent or greater yield than manual production.”

[biosectinvestor]

See also, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5946316/



“Automated generation of immature dendritic cells in a single-use system

Andrew Kozbial, Lekhana Bhandary, [...], and Shashi K. Murthy

Additional article information

Associated Data

Supplementary Materials
Abstract

Dendritic cells (DCs) are an indispensable part of studying human responses that are important for protective immunity against cancer and infectious diseases as well as prevention of autoimmunity and transplant rejection. These cells are also key elements of personalized vaccines for cancer and infectious diseases. Despite the vital role of DCs in both clinical and basic research contexts, methods for obtaining these cells from individuals remains a comparatively under-developed and inefficient process. DCs are present in very low concentrations (<1%) in blood, thus they must be generated from monocytes and the current methodology in DC generation involves a laborious process of static culture and stimulation with cytokines contained in culture medium. Herein, we describe an automated fluidic system, MicroDEN, that allows for differentiation of monocytes into immature-DCs (iDCs) utilizing continuous perfusion of differentiation media. Manual steps associated with current ex vivo monocyte differentiation are vastly reduced and an aseptic environment is ensured by the use of an enclosed cartridge and tubing network. Benchmark phenotyping was performed on the generated iDCs along with allogeneic T-cell proliferation and syngeneic antigen-specific functional assays. MicroDEN generated iDCs were phenotypically and functionally similar to well plate generated iDCs, thereby demonstrating the feasibility of utilizing MicroDEN in the broad range of applications requiring DCs.

Keywords: Dendritic cell, Monocyte, Vaccine, Cancer vaccinology, Antigen-presenting cell, Personalized medicine
”